XPro1595
Oncology (Various Solid Tumors)
Phase 1/2Active
Key Facts
About INmune Bio
INmune Bio is a clinical-stage biotech focused on precisely modulating the innate immune system to treat Alzheimer's disease and cancer. Its strategy centers on two distinct platforms: XPro1595, a dominant-negative TNF inhibitor that neutralizes only the soluble form driving pathology, and INKmune, an in vivo NK cell primer. The company is advancing multiple Phase 2 trials, with a development philosophy anchored in patient biology and clinically relevant metrics.
View full company profileTherapeutic Areas
Other Oncology (Various Solid Tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| PreTarg-it® Programs | OncoOne | Preclinical/Discovery |